ArticleCancer reports (Hoboken, N.J.)2025
Risk Factors and Vascular Features Associated With Local Recurrence in Pancreatic Cancer Post-Pancreaticoduodenectomy: A Retrospective Cohort Study.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Research progress on the etiology and pathogenesis of pancreatic cancer: a narrative review.Frontiers in oncology · 2026Review
- Risk Factors and Vascular Features Associated With Local Recurrence in Pancreatic Cancer Post-Pancreaticoduodenectomy: A Retrospective Cohort Study.Cancer reports (Hoboken, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aims to analyze the risk factors for local recurrence (LR) following pancreaticoduodenectomy (PD) in pancreatic cancer patients and to identify vascular features associated with this outcome.
backgroundPancreatic cancer frequently involves the mesenteric root, particularly the Porto-mesenteric vein (PV-SMV), impacting survival post curative surgery. However, the relationship between vascular structural changes and LR post-operation remains unclear.
methodsRetrospective data collection was conducted at a single tertiary center from December 2010 to March 2021. Clinical characteristics, surgical-pathological factors, and radiological features were compiled.
resultsA total of 203 pancreatic cancer cases undergoing PD were analyzed, with 72 (35.5%) undergoing concurrent PV-SMV resection (VR). Median overall survival post-operation was 22.4 months. LR occurred in 121 patients (60%) at a median time of 8 months postoperatively. Resectable disease exhibited significantly longer local-recurrence free survival compared to borderline resectable/locally advanced pancreatic cancer (BRPC/LAPC) (median 14.5 vs. 7 months, p < 0.001). The most frequent sites of LR were the mesenteric root (37%), superior mesenteric artery (SMA, 21%), and superior mesenteric vein (SMV, 16%), with similar patterns observed in the VR and non-VR groups. BRPC, LAPC, postoperative CA19-9 above normal range, venous thrombosis, and stenosis were associated with LR (HR: 2.1 [95% CI 1.21-3.68], 2.7 [95% CI 1.6-4.71], 1.8 [95% CI 1.21-2.69], 2.0 [95% CI 1.08-3.92], and 1.6 [95% CI 1.0-2.65], respectively), while PV-SMV resection and enlargement of PV-SMV angle were protective factors (HR: 0.4 [95% CI 0.25-0.67] and 0.3 [95% CI 0.19-0.53]).
conclusionsDespite aggressive treatment strategies including neoadjuvant therapy and radical surgery, LR in pancreatic cancer remains a challenge. This study highlights potential risk factors, recurrence patterns, and associated vascular features for early identification. These findings may guide clinicians in developing more targeted surveillance strategies and inform future research on preventing LR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.